PubMed ID: 36795065 Author(s): Chua SYL, Welsh P, Sun Z, Balaskas K, Warwick A, Steel D, Sivaprasad S, Channa R, Ko T, Sattar N, Khawaja AP, Foster PJ, Patel PJ; UK Biobank Eye and Vision …
All Posts
Intra-arterial chemotherapy in refractory and advanced intraocular retinoblastoma.
PubMed ID: 36727336 Author(s): Kumari N, Jain N, Saboo S, Parthasarathy R, Gupta V, Mahajan A, Das S. Intra-arterial chemotherapy in refractory and advanced intraocular retinoblastoma. Indian J Ophthalmol. 2023 Feb;71(2):436-443. doi: 10.4103/ijo.IJO_1388_22. PMID 36727336 …
Commentary: Can machine be taught to detect retinoblastoma?
PubMed ID: 36727334 Author(s): Das S, Varshney A. Commentary: Can machine be taught to detect retinoblastoma? Indian J Ophthalmol. 2023 Feb;71(2):432-433. doi: 10.4103/ijo.IJO_2283_22. No abstract available. PMID 36727334 Journal: Indian Journal Of Ophthalmology, Volume 71, …
UW’s Low Vision Rehabilitation Offers Comprehensive Services to Patients
The National Eye Institute recognizes February as Low Vision Awareness Month. This places a spotlight on vision-related disabilities and the supportive infrastructure needed.
Cytochrome P450 1B1 Expression Regulates Intracellular Iron Levels and Oxidative Stress in the Retinal Endothelium.
PubMed ID: 36768740 Author(s): Song YS, Zaitoun IS, Wang S, Darjatmoko SR, Sorenson CM, Sheibani N. Cytochrome P450 1B1 Expression Regulates Intracellular Iron Levels and Oxidative Stress in the Retinal Endothelium. Int J Mol Sci. …
SANDCAT
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema (Sandcat)
CapriCORN
Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the Cornea
RECORDATI MT8
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops (MT8) for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
IMVT TED
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)